Lenvatinib in Locally Advanced Invasive Thyroid Cancer

Summary

This research is being done to evaluate the safety and efficacy of neoadjuvant lenvatinib on surgical outcomes of patients with invasive extrathyroidal differentiated thyroid cancer (DTC). This research study involves a study drug called lenvatinib

Timeline

Start

2021-03-09

Primary completion

2025-05-27

Completion

2026-05-27

Publications

• Farlow JL, McCrary HC, Sipos JA, Phay JE, Konda B, Agrawal A. Neoadjuvant dabrafenib and trametinib for functional organ preservation in recurrent BRAF V600E-mutated papillary thyroid cancer. Oral Oncol. 2023 Dec;147:106625. doi: 10.1016/j.oraloncology.2023.106625. Epub 2023 Nov 8.

Drugs

Indications